• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Outcomes after Resection of Intrahepatic Cholangiocarcinoma: External Validation and Comparison of Prognostic Models.肝内胆管癌切除术后的预后:预后模型的外部验证与比较
J Am Coll Surg. 2015 Aug;221(2):452-61. doi: 10.1016/j.jamcollsurg.2015.04.009. Epub 2015 Apr 24.
2
A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience.列线图预测肝内胆管细胞癌切除术后的长期生存:东西方经验。
JAMA Surg. 2014 May;149(5):432-8. doi: 10.1001/jamasurg.2013.5168.
3
The prognostic value of sarcopenia combined with preoperative fibrinogen-albumin ratio in patients with intrahepatic cholangiocarcinoma after surgery: A multicenter, prospective study.术后肝内胆管癌患者肌少症联合术前纤维蛋白原-白蛋白比值的预后价值:一项多中心前瞻性研究。
Cancer Med. 2021 Jul;10(14):4768-4780. doi: 10.1002/cam4.4035. Epub 2021 Jun 8.
4
Prognostic value of lymphadenectomy for long-term outcomes in node-negative intrahepatic cholangiocarcinoma: A multicenter study.淋巴结清扫术对淋巴结阴性的肝内胆管癌长期预后的预测价值:一项多中心研究。
Surgery. 2019 Dec;166(6):975-982. doi: 10.1016/j.surg.2019.06.025. Epub 2019 Aug 14.
5
A Prognostic Nomogram for Overall Survival of Patients After Hepatectomy for Intrahepatic Cholangiocarcinoma.肝内胆管癌肝切除术后患者总生存的预后列线图
Anticancer Res. 2016 Aug;36(8):4249-58.
6
Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy.肝内胆管癌根治性切除术后的预后列线图。
J Clin Oncol. 2013 Mar 20;31(9):1188-95. doi: 10.1200/JCO.2012.41.5984. Epub 2013 Jan 28.
7
Model to predict survival after surgical resection of intrahepatic cholangiocarcinoma: the Mayo Clinic experience.预测肝内胆管癌手术切除后生存率的模型:梅奥诊所的经验
HPB (Oxford). 2015 Mar;17(3):244-50. doi: 10.1111/hpb.12333. Epub 2014 Nov 19.
8
Preoperative risk score for prediction of long-term outcomes after hepatectomy for intrahepatic cholangiocarcinoma: Report of a collaborative, international-based, external validation study.肝内胆管细胞癌肝切除术后长期预后预测的术前风险评分:一项协作性、国际、外部验证研究的报告。
Eur J Surg Oncol. 2020 Apr;46(4 Pt A):560-571. doi: 10.1016/j.ejso.2019.10.041. Epub 2019 Nov 5.
9
A nomogram to predict lymph node metastasis before resection in intrahepatic cholangiocarcinoma.一种用于预测肝内胆管癌切除术前淋巴结转移的列线图。
J Surg Res. 2018 Jun;226:56-63. doi: 10.1016/j.jss.2018.01.024. Epub 2018 Feb 10.
10
A new prognostic scoring system using factors available preoperatively to predict survival after operative resection of perihilar cholangiocarcinoma.一种新的预后评分系统,利用术前可得因素预测肝门周围胆管癌手术切除后的生存情况。
Surgery. 2016 Mar;159(3):842-51. doi: 10.1016/j.surg.2015.10.027. Epub 2015 Dec 10.

引用本文的文献

1
Role of Particle Therapy for Intrahepatic Cholangiocarcinoma; Meta-Analysis for Comparison with Standard Therapy: TRP-Intrahepatic Cholangiocarcinoma 2025.粒子治疗在肝内胆管癌中的作用;与标准治疗比较的荟萃分析:TRP-肝内胆管癌2025
Liver Cancer. 2025 Jun 22. doi: 10.1159/000546559.
2
Introducing and Validating the Multiphasic Evidential Decision-Making Matrix (MedMax) for Clinical Management in Patients with Intrahepatic Cholangiocarcinoma.介绍并验证用于肝内胆管癌患者临床管理的多相循证决策矩阵(MedMax)。
Cancers (Basel). 2024 Dec 27;17(1):52. doi: 10.3390/cancers17010052.
3
Perioperative infections as a prognostic risk factor in hepatocellular carcinoma and cholangiocellular carcinoma: a comparative analysis.围手术期感染作为肝细胞癌和胆管细胞癌的预后危险因素:一项对比分析。
World J Surg Oncol. 2025 Jan 7;23(1):9. doi: 10.1186/s12957-024-03651-8.
4
[Cholangiocarcinomas].[胆管癌]
Chirurgie (Heidelb). 2025 Jan;96(1):77-86. doi: 10.1007/s00104-024-02200-z. Epub 2024 Dec 10.
5
Knockdown of long noncoding RNA AL161431.1 inhibits malignant progression of cholangiocarcinoma.敲低长链非编码 RNA AL161431.1 抑制胆管癌的恶性进展。
Aging (Albany NY). 2024 Aug 1;16(15):11501-11512. doi: 10.18632/aging.205898.
6
Clinical outcomes and risk stratification in unresectable biliary tract cancers undergoing radiation therapy.不可切除胆道癌患者接受放射治疗的临床结果和风险分层。
Radiat Oncol. 2024 Aug 1;19(1):102. doi: 10.1186/s13014-024-02481-y.
7
GAL3ST1 Deficiency Reduces Epithelial-Mesenchymal Transition and Tumorigenic Capacity in a Cholangiocarcinoma Cell Line.GAL3ST1 缺乏可降低胆管癌细胞系中的上皮-间充质转化和致瘤能力。
Int J Mol Sci. 2024 Jul 2;25(13):7279. doi: 10.3390/ijms25137279.
8
Cholangiocarcinoma imaging: from diagnosis to response assessment.胆管癌影像学:从诊断到疗效评估。
Abdom Radiol (NY). 2024 May;49(5):1699-1715. doi: 10.1007/s00261-024-04267-y. Epub 2024 Apr 5.
9
Using immunovascular characteristics to predict very early recurrence and prognosis of resectable intrahepatic cholangiocarcinoma.利用免疫血管特征预测可切除性肝内胆管癌的极早期复发和预后。
BMC Cancer. 2023 Oct 19;23(1):1009. doi: 10.1186/s12885-023-11476-z.
10
A CT-based radiomics approach to predict intra-tumoral tertiary lymphoid structures and recurrence of intrahepatic cholangiocarcinoma.一种基于CT的放射组学方法用于预测肝内胆管癌的瘤内三级淋巴结构和复发情况。
Insights Imaging. 2023 Oct 15;14(1):173. doi: 10.1186/s13244-023-01527-1.

本文引用的文献

1
Defining the Benefit of Adjuvant Therapy Following Resection for Intrahepatic Cholangiocarcinoma.确定肝内胆管癌切除术后辅助治疗的益处。
Ann Surg Oncol. 2015 Jul;22(7):2209-17. doi: 10.1245/s10434-014-4275-4. Epub 2014 Dec 5.
2
Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma: Systematic Review and Meta-analysis.肝内胆管细胞癌患者的治疗与预后:系统评价和荟萃分析。
JAMA Surg. 2014 Jun;149(6):565-74. doi: 10.1001/jamasurg.2013.5137.
3
A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience.列线图预测肝内胆管细胞癌切除术后的长期生存:东西方经验。
JAMA Surg. 2014 May;149(5):432-8. doi: 10.1001/jamasurg.2013.5168.
4
Liver enzymes and risk of all-cause mortality in general populations: a systematic review and meta-analysis.普通人群中肝酶与全因死亡率风险:一项系统评价与荟萃分析
Int J Epidemiol. 2014 Feb;43(1):187-201. doi: 10.1093/ije/dyt192.
5
Routine lymph node dissection may be not suitable for all intrahepatic cholangiocarcinoma patients: results of a monocentric series.常规淋巴结清扫术可能并不适用于所有肝内胆管细胞癌患者:一项单中心系列研究的结果。
World J Gastroenterol. 2013 Dec 21;19(47):9084-91. doi: 10.3748/wjg.v19.i47.9084.
6
Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials.顺铂和吉西他滨治疗晚期胆道癌:两项随机试验的荟萃分析。
Ann Oncol. 2014 Feb;25(2):391-8. doi: 10.1093/annonc/mdt540. Epub 2013 Dec 18.
7
Multidisciplinary approaches to intrahepatic cholangiocarcinoma.多学科方法治疗肝内胆管细胞癌。
Cancer. 2013 Nov 15;119(22):3929-42. doi: 10.1002/cncr.28312. Epub 2013 Aug 20.
8
Recurrence after operative management of intrahepatic cholangiocarcinoma.肝内胆管细胞癌手术后的复发。
Surgery. 2013 Jun;153(6):811-8. doi: 10.1016/j.surg.2012.12.005. Epub 2013 Mar 15.
9
Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy.肝内胆管癌根治性切除术后的预后列线图。
J Clin Oncol. 2013 Mar 20;31(9):1188-95. doi: 10.1200/JCO.2012.41.5984. Epub 2013 Jan 28.
10
Prevalence of nonalcoholic steatohepatitis among patients with resectable intrahepatic cholangiocarcinoma.可切除性肝内胆管细胞癌患者中非酒精性脂肪性肝炎的患病率。
J Gastrointest Surg. 2013 Apr;17(4):748-55. doi: 10.1007/s11605-013-2149-x. Epub 2013 Jan 25.

肝内胆管癌切除术后的预后:预后模型的外部验证与比较

Outcomes after Resection of Intrahepatic Cholangiocarcinoma: External Validation and Comparison of Prognostic Models.

作者信息

Doussot Alexandre, Groot-Koerkamp Bas, Wiggers Jimme K, Chou Joanne, Gonen Mithat, DeMatteo Ronald P, Allen Peter J, Kingham T Peter, D'Angelica Michael I, Jarnagin William R

机构信息

Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.

Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.

出版信息

J Am Coll Surg. 2015 Aug;221(2):452-61. doi: 10.1016/j.jamcollsurg.2015.04.009. Epub 2015 Apr 24.

DOI:10.1016/j.jamcollsurg.2015.04.009
PMID:26206643
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4784264/
Abstract

BACKGROUND

Published prognostic models for overall survival after liver resection for intrahepatic cholangiocarcinoma require external validation before use in clinical practice.

STUDY DESIGN

From January 1993 to May 2013, consecutive patients who underwent resection of intrahepatic cholangiocarcinoma were identified from a prospective database. The Wang nomogram was derived in an Asian cohort (n = 367) and included clinicopathologic variables and preoperative CEA and cancer antigen 19-9 levels. The Hyder nomogram was derived in an Eastern and Western multicenter cohort (n = 514) using clinicopathologic variables only. The AJCC Cancer Staging System (7th ed) and the preoperative Fudan risk score were also evaluated. Prognostic performance was assessed in terms of discrimination, calibration, and stratification.

RESULTS

One hundred and eighty-eight patients were included, with a median follow-up of 41 months. Median overall survival was 48.7 months and estimated 3-year and 5-year overall survival rates were 59% and 45%, respectively. Overall survival prediction accuracy, according to concordance-index calculation, was 0.72 with the Wang nomogram, 0.66 with the Hyder nomogram, 0.63 with the AJCC system, and 0.55 using the Fudan score. Both nomograms provided effective patient stratification in distinct survival groups.

CONCLUSIONS

Both the Wang and Hyder nomograms provided accurate patient prognosis estimation after liver resection for intrahepatic cholangiocarcinoma and can be useful for decision making about adjuvant therapy. The Wang nomogram appears to be more appropriate in patients undergoing formal portal lymphadenectomy and requires preoperative CEA and cancer antigen 19-9 levels for optimal performance.

摘要

背景

已发表的肝内胆管癌肝切除术后总生存预后模型在临床实践中应用前需要进行外部验证。

研究设计

从1993年1月至2013年5月,从前瞻性数据库中识别出连续接受肝内胆管癌切除术的患者。王式列线图来自一个亚洲队列(n = 367),包括临床病理变量以及术前癌胚抗原(CEA)和癌抗原19-9水平。海德列线图来自一个东西方多中心队列(n = 514),仅使用临床病理变量。还评估了美国癌症联合委员会(AJCC)癌症分期系统(第7版)和术前复旦大学风险评分。从区分度、校准度和分层方面评估预后性能。

结果

纳入188例患者,中位随访时间为41个月。中位总生存时间为48.7个月,估计3年和5年总生存率分别为59%和45%。根据一致性指数计算,王式列线图的总生存预测准确率为0.72,海德列线图为0.66,AJCC系统为0.63,复旦大学评分法为0.55。两种列线图均能在不同生存组中对患者进行有效分层。

结论

王式和海德列线图在肝内胆管癌肝切除术后均能准确估计患者预后,可用于辅助治疗的决策制定。王式列线图似乎更适用于接受正规门静脉淋巴结清扫术的患者,并且需要术前CEA和癌抗原19-9水平以达到最佳性能。